NCT04795960撤回不适用
Microbiome Modification to Enhance Stelara Response in Crohn's Disease
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- The mean simple endoscopic subscore Crohn's disease (SES-CD) score at week 25 between the two treatment groups.
研究概览
简要总结
This pilot study is being completed to determine whether a low-serine diet vs a high serine diet will reduce inflammation and symptoms in Crohn's disease (CD), as well as determine whether a low-serine diet (vs. a high serine diet) will improve responses in patients initiating therapy with Ustekinumab (Stelara), an FDA-approved biologic therapy for Crohn's disease.
详细描述
Eligible participants that will be given Ustekinumab as part of their standard of care will be enrolled in this study.
The study hypotheses include that a low serine diet (compared to a high serine diet) in patients with active CD will:
- Reduce the relative abundance of Adherent invasive ecoli (AIEC), and increase the relative abundance of Bacteroides and Faecalibacterium in stool of patients with Crohn's disease.
- Make patients more likely to respond to ustekinumab (anti-Interleukin12/23) therapy with control of inflammation as measured by the mean Simple endoscopic subscore Crohn's disease (SES-CD) in each group at week 25.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of Crohn's Disease (CD) for at least 3 months prior to baseline. Appropriate documentation of biopsy results consistent with the diagnosis of CD, as determined by the investigator.
- •Simple endoscopic subscore Crohn's disease (SES-CD) ≥ 7 for ileocolonic CD (or >=4 if only ileal CD) as confirmed by Dr. Higgins' scoring of colonoscopy.
- •Are scheduled to begin Ustekinumab within the next 7-60 days
- •Must be scheduled for clinically indicated colonoscopy, ordered by primary Gastroenterologist physician, and covered by insurance
- •Must have access to a computer capable of completing video visits
- •Must be willing to follow assigned meat-free diet provided by the study exclusively for 2 weeks
- •Patients on anti-diarrheals must be on a stable dose for at least 2 weeks
- •Prednisone is allowed up to a daily dose of 20 mg, with a stable dose for at least 1 week
排除标准
- •Subject with a current diagnosis of Ulcerative Colitis
- •Subjects requiring or receiving any Total Parenteral Nutrition (TPN) and/or exclusive enteral nutrition.
- •Subjects who are pregnant or plan to become pregnant over the duration of the study
- •Antibiotics in the previous 2 weeks.
- •Probiotics in the previous 2 weeks.
- •Ongoing therapy with infliximab, adalimumab, certolizumab, vedolizumab, or tofacitinib, is not allowed - must stop at least 1 week prior to ustekinumab start.
- •Changes in dose of 5-aminosalicylates within the past 1 week - must be on a stable dose for at least one week.
- •Changes in dose of immunomodulators (including Azathioprine, 6-mercaptopurine, methotrexate) within the past 4 weeks - must be on a stable dose for 4 weeks.
- •Subjects with the following known complications of CD; Toxic megacolon, Short bowel syndrome or short gut (less than 100 centimeters, Ostomy, Symptomatic bowel strictures (scope cannot be passed through), any diagnosis that could interfere with nutrient absorption, note that actively draining fistulas are allowed at entry.
- •Subjects who use dietary supplements such as liquid or powder protein drinks/shakes, meal replacement shakes, and fiber supplements, etc. must be willing to stop at least 24 hours prior to starting the assigned diet
- •Known allergy to soy products
- •Oral Iron must be stopped at least 24 hours prior to baseline
- •For severe anemia, intravenous (IV) iron can replace oral iron if approved and ordered by the prescribing physician
- •Any subject currently hospitalized
- •Any subject with a positive Clostridium difficile test (within 30 days of baseline) or currently being treated for Clostridium difficile.
- •History of clinically significant medical condition or any other reason which, in the opinion of the PI, would interfere with the subject's participation
- •Any active, chronic or recurrent infection that, based on the investigator's clinical assessment, makes the subject an unsuitable candidate for the study.
结局指标
主要结局
The mean simple endoscopic subscore Crohn's disease (SES-CD) score at week 25 between the two treatment groups.
时间窗: 25 weeks
This will be calculated by endoscopist at week 25.
次要结局
- The mean Crohn's disease patient report outcomes (CD-PRO) score at week 2 will be compared between the two groups with Student's t test(2 weeks)
- The mean CD-PRO scores calculated by study team at week 25 will be compared between the two groups with Student's t test.(25 weeks)
研究者
Peter Higgins
Professor of Internal Medicine
University of Michigan
研究点 (2)
Loading locations...
相似试验
已完成
早期 1 期
Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint InhibitorsSolid TumorNCT04552418University of Michigan Rogel Cancer Center12
Unknown
不适用
Gut Microbiome Modification Through Dietary Intervention in Patients With Colorectal Cancer: Response to SurgeryColorectal CancerNCT04869956Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia50
招募中
不适用
Impact of Microbiome-changing Interventions on Food Decision-makingOverweight and ObesityNCT05353504Max Planck Institute for Human Cognitive and Brain Sciences90
已完成
不适用
Targeting the Microbiome to Improve Clinical Outcomes in Bipolar DisorderBipolar DisorderNCT02855762Melvin McInnis, MD10
已完成
2 期
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT PatientsHematopoietic Stem Cell TransplantationNCT02763033University of Michigan Rogel Cancer Center107